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This paper discusses a rare case of renal metastatic osteosarcoma. A 25-year-old man with a history of metastatic osteosarcoma
involving his right kidney was referred to our institution for treatment. He was managed with chemotherapy. An exhaustive
review of the English literature pertaining to this disease was performed. To our knowledge, this case represents only the sixteenth.
The literature suggests that the incidence of renal involvement in osteosarcoma is signiﬁcant and that the treatment should be
multidisciplinary in such patients.
1.Introduction
Renal metastases from osteosarcoma are extremely rare.
We present a case of a young male with osteosarcoma of
the left femur who developed late recurrence in the form
of large metastatic renal and pulmonary lesions. Review
of the literature suggests that osteosarcoma metastases of
the kidneys usually exhibit aggressive behaviour with poor
prognosis. However, local and systemic relapses are possible,
even5ormoreyearssincethebeginningoftreatment,along-
term followup is recommended.
2.CaseReport
A 25-year-old male was diagnosed in 2004 as a femur
osteosarcomawithnoevidenceofdistancemetastases.Initial
treatment was by resection of the primary tumour with
adjuvant chemotherapy.
Thereafter, he remained well until April 2010 when he
presented with a 6-week history of painless haematuria
and painful masse in the lumbar region. Abdominal CT
scan revealed a renal masse (Figure 1). This entity has
not been previously described and the initial suspicion was
that the patient had developed a further primary tumour.
An ultrasound-guided ﬁne needle biopsy conﬁrmed the
diagnosisofmetastases.Chestcomputerscanshowedpleural
metastases (Figure 2).
Preoperative chemotherapy based on API regimen (adri-
ablastin 60mg/m2 D1, ifosfamide 1,8g/m2 D1–D5, mesna
1,8g/m2 D1–D5, cisplatin 60mg/m2 D2) is started. A
thoracoabdominal computer tomography scan after the
3 cycles of chemotherapy demonstrated that the lesions
enlarged rapidly, a second regimen of chemotherapy based
on cisplatin and etoposide was programmed.
3. Discussion
Osteosarcoma is the most frequent malignant tumor of
bones. The peak incidence occurs in the second decade of
life, and the metaphyseal part of long bones is the site most
frequently involved.
Classical high-grade osteosarcoma of the extremity has
moreofatendencytometastasize,unlikelow-gradeparosteal
osteosarcomas.
Primary osteosarcoma is a highly aggressive tumor that
metastasizes by hematogenous dissemination. At diagnosis,
nearly all patients will have microscopic metastases [1].2 Case Reports in Urology
Figure 1: Abdominal computed tomography scan revealed renal
metastases of osteosarcoma.
Despite resection and chemotherapy, 30%–40% of patients
with localized disease will experience relapse, usually within
3y e a r s[ 2]. In Our case, the patient experienced relapse
6 years after the treatment. Once this happens, the overall
survival ranges from 13% to 57% [3, 4].
The lung is the most common site of metastatic disease,
and the rarer instances of soft tissue and solid organ
metastases have been considered preterminal, however,
extrapulmonary sites are increasingly aﬀected in treated
patients.Thismaybebecauseofchangeinthenaturalhistory
of the disease by multiagent chemotherapy or longer survival
times of these patients [1, 5]. In fact, the most commonly
aﬀected extrapulmonary site is the skeletal system followed
by brain, liver, pelvis, and soft tissues. In the current case,
kidney is aﬀected.
The reported incidence of renal metastasis of extrarenal
neoplasms varies from 2 to 20% [6]. Renal metastasis of
osteosarcoma is usually detected after death as part of
widespread disease 10–12% of patient autopsies showed
renal involvement [7, 8]. Whereas 15% of patients will
have clinically detectable lung metastases at diagnosis, renal
metastases are usually silent [1].
Premortem diagnosis of renal metastasis is rare [1]. An
intensive review of the literature demonstrates only 16 cases
ofpremortemdiagnosisofrenalinvolvementamongpatients
with osteosarcoma [5, 9–11].
When osteosarcoma of the kidney is discovered,
metastatic disease from a bone primary is more likely than a
primary lesion. Also, the presentation of these entities tends
to diﬀer.
Previous studies suggested that renal metastases of
osteosarcoma were usually detected 2.2 years after the
primary diagnosis. However, a more recent literature review
found a mean interval of 62 months from time of treatment
of primary tumor to diagnosis of renal metastases [12].
Hallet et al. reported on a patient whose renal metastasis
w a sf o u n d1 4y e a r sa f t e rt r e a t m e n to ft h ep r i m a r yt u m o r
Figure 2: Chest computed scan revealed pleural metastases.
[13].However,asdemonstratedbyourcaseandthatofAyres
et al., these lesions have the potential to enlarge rapidly [14].
The earliest report of renal involvement by osteosarcoma
is likely from a case involving a 15-year-old girl described by
Weber in 1931 [15].
Most surveillance protocols after primary resection of
osteosarcoma involve radiographic imaging of the bones
and lungs. The abdomen is not routinely evaluated. Before
the development of ultrasonography and CT, renal lesions
in osteosarcoma were detected by intravenous pyelogram
or, rarely, as areas of increased calciﬁcation on abdominal
radiographs [16]. Unfortunately, in contrast with primary
renal osteosarcoma, metastatic lesions usually do not possess
enough calciﬁcation to be seen on simple radiographs [17].
In the contemporary setting, it is likely that most renal
metastases will be detected by CT. Interestingly, however,
a previous report found a patient’s disease was missed by
radiograph and CT and detected only by an abnormality on
bone scan [13].
The diagnosis of metastatic disease should be made by
imaging because some authors have expressed concern that
needle biopsies risk dissemination of disease that is likely to
be chemoradiation therapy resistant [18].
FDG-PET is sometimes used to conﬁrm suspected
pulmonary metastases seen on CT. Some believe that this
modality is useful in detecting distant recurrences, especially
in patients with extensive surgical histories or previous
radiation therapy [19]. However, FDG-PET appears to be of
limited usefulness in patients with osteosarcoma [20]. This
might change with time as other positron emitter isotopes
are developed.
Over the past 30 years, the 5-year survival for patients
with osteosarcoma has dramatically improved from 10%
to 70%. Surprisingly, however, the most eﬀective regimen
of chemotherapy uses the same agents that have been
used for the past 20 years, namely, doxorubicin, cisplatin,
methotrexate, and ifosfamide. Among treatment-related
variables, only complete surgery has been reliably linked toCase Reports in Urology 3
improvedsurvival.However,manycontendthatadjustments
in the combination of chemotherapy and surgery are largely
responsible [2].
4. Conclusion
Improvements in multimodal treatment for osteosarcoma,
especially in the use of adjuvant chemotherapy, have
increased event-free and overall survival. Meanwhile, the
prolonged survival of patients has permitted the appearance
of new signiﬁcant, extra pulmonary targets for metastasis
such as renal metastases. Ultimately, urologic, orthopedic,
and general surgeons as well as radiologists and medical
oncologists need to be thoroughly educated in regard to this
entity because a multidisciplinary approach is ideal for these
patients.
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